AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9293327 — intervention group
Group type: COMPARATOR
Intervention: Sterile prep kits
Number of subjects: 60
Study 8101304 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning (short periods of ischaemia with intermittent reperfusion)
Number of subjects: 0
Study 8101304 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of adenosine triphosphate in biopsy specimens
Number of subjects: 0
Study 3582518 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline therapy (5 days oral administration)
Number of subjects: 0
Study 3582518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30766567 — intervention group
Group type: EXPERIMENTAL
Intervention: PASCAL laser
Number of subjects: 28
Study 30766567 — intervention group
Group type: COMPARATOR
Intervention: Conventional laser
Number of subjects: 28
Study 27557705 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief case management for 4 to 6 months
Number of subjects: 166
Study 27557705 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 166
Study 26573809 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational materials plus coach training (COACH)
Number of subjects: 2
Study 26573809 — intervention group
Group type: COMPARATOR
Intervention: Printed educational materials only (PEM)
Number of subjects: 2
Study 22990943 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram or Nortriptyline
Number of subjects: 108
Study 16184460 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (25 mg/day)
Number of subjects: 176
Study 16184460 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 176
Study 12847070 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase + Enoxaparin (30 mg IV bolus followed by 1 mg/kg SC BID for 7 days)
Number of subjects: 1639
Study 12847070 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase + Enoxaparin
Number of subjects: 1639
Study 12847070 — intervention group
Group type: COMPARATOR
Intervention: Tenecteplase + Unfractionated Heparin (UFH)
Number of subjects: 1639
Study 9741753 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery-type words
Number of subjects: 25
Study 9741753 — intervention group
Group type: COMPARATOR
Intervention: Abstract-type words
Number of subjects: 25
Study 7793887 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg daily oral doses for at least 3 weeks
Number of subjects: 4
Study 2338029 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous S/A (1.0/2.0 g)
Number of subjects: 10
Study 2338029 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous S/A (0.5/1.0 g)
Number of subjects: 10
Study 2338029 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular S/A (0.5/1.0 g)
Number of subjects: 10
Study 380913 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg once daily)
Number of subjects: 24
Study 380913 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (25 mg 3-times daily)
Number of subjects: 24
Study 380913 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (400 mg 3-times daily)
Number of subjects: 24
Study 380913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29771148 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous needle electrolysis (n = 39)
Number of subjects: 73
Study 29771148 — intervention group
Group type: COMPARATOR
Intervention: Placebo puncture (n = 34)
Number of subjects: 73
Study 27733180 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin (5 mg) administered once daily for 12 weeks
Number of subjects: 42
Study 27733180 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study 25675797 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral feeding (EOF) after regional anesthesia (n=49)
Number of subjects: 200
Study 25675797 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral feeding (EOF) after general anesthesia (n=48)
Number of subjects: 200
Study 25675797 — intervention group
Group type: COMPARATOR
Intervention: Routine oral feeding (ROF) after regional anesthesia (n=47)
Number of subjects: 200
Study 25675797 — intervention group
Group type: COMPARATOR
Intervention: Routine oral feeding (ROF) after general anesthesia (n=48)
Number of subjects: 200
Study 23867008 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV self-sampling
Number of subjects: 1000
Study 23867008 — intervention group
Group type: COMPARATOR
Intervention: Flexible outpatient clinic appointments
Number of subjects: 1000
Study 20392575 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus CBT4CBT
Number of subjects: 77
Study 20392575 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 77
Study 18191416 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (monotherapy)
Number of subjects: 162
Study 18191416 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 162
Study 15679698 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral eletriptan 80 mg
Number of subjects: 311
Study 15679698 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous sumatriptan 6 mg (suma-sc)
Number of subjects: 311
Study 12091866 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) once per week for 6 weeks + 6 sessions of cognitive-behavioral treatment
Number of subjects: 28
Study 12091866 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) 3 times per week for 6 weeks + 6 sessions of cognitive-behavioral treatment
Number of subjects: 28
Study 12091866 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study 10346773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 501
Study 10346773 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 501
Study 9816048 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxyamido-triazole (CAI) liquid formulation at doses of 100, 125, and 150 mg/m2/day and 200 and 330 mg/m2 every other day
Number of subjects: 39
Study 9816048 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxyamido-triazole (CAI) gelcap formulation at doses of 100 and 125 mg/m2/day and 200 mg/m2 every other day
Number of subjects: 39
Study 9816048 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxyamido-triazole (CAI)
Number of subjects: 39
Study 1675316 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (20-160 mg twice daily)
Number of subjects: 54
Study 1675316 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 54
Study 7449302 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (average daily dose 240 mg)
Number of subjects: 55
Study 7449302 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (Control)
Number of subjects: 55
Study 31528865 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried bone allograft with collagen wound dressing (test 2 group)
Number of subjects: 21
Study 31528865 — intervention group
Group type: COMPARATOR
Intervention: Collagen wound dressing alone (control group)
Number of subjects: 21
Study 31528865 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried bone allograft with dense polytetrafluoroethylene membrane (test 1 group)
Number of subjects: 21
Study 28176302 — intervention group
Group type: EXPERIMENTAL
Intervention: Educare
Number of subjects: 239
Study 28176302 — intervention group
Group type: COMPARATOR
Intervention: Business-as-usual control group
Number of subjects: 239
Study 25957440 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 25957440 — intervention group
Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 0
Study 25957440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23357561 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level stepped intervention to increase CRC screening rates
Number of subjects: 0
Study 23357561 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 21249417 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical and educational intervention (Group 1) consisting of relaxation and posture exercises and the use of visual feedback.
Number of subjects: 384
Study 21249417 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2) received the same intervention after 6 months.
Number of subjects: 384
Study 18620344 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral position (RLP) after swallowing the capsule
Number of subjects: 0
Study 18620344 — intervention group
Group type: COMPARATOR
Intervention: Non-right lateral position (standing up position)
Number of subjects: 0
Study 17030153 — intervention group
Group type: EXPERIMENTAL
Intervention: AudioScope screening
Number of subjects: 2305
Study 17030153 — intervention group
Group type: EXPERIMENTAL
Intervention: HHIE-S screening
Number of subjects: 2305
Study 17030153 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined screening (AudioScope + HHIE-S)
Number of subjects: 2305
Study 17030153 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no screening)
Number of subjects: 2305
Study 15129412 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait retraining with the FDHO model
Number of subjects: 16
Study 15129412 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait retraining with the PSF
Number of subjects: 16
Study 15129412 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 16
Study 11461943 — intervention group
Group type: COMPARATOR
Intervention: L-NAME + Placebo (PL)
Number of subjects: 7
Study 11461943 — intervention group
Group type: COMPARATOR
Intervention: L-NAME + Losartan (LOS)
Number of subjects: 7
Study 11461943 — intervention group
Group type: COMPARATOR
Intervention: L-NAME + Indomethacin (IND)
Number of subjects: 7
Study 11461943 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NAME + Indomethacin + Losartan (IND + LOS)
Number of subjects: 7
Study 9712594 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcoital test included in infertility investigations
Number of subjects: 444
Study 9712594 — intervention group
Group type: COMPARATOR
Intervention: Control group (series excluding the postcoital test)
Number of subjects: 444
Study 7978092 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 0.5 g/kg
Number of subjects: 10
Study 7978092 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 0.9 g/kg
Number of subjects: 10
Study 7978092 — intervention group
Group type: COMPARATOR
Intervention: Control (Ethanol 0.0 g/kg)
Number of subjects: 10
Study 2532682 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclobenzaprine
Number of subjects: 7
Study 2532682 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study 1203854 — intervention group
Group type: EXPERIMENTAL
Intervention: POMP (prednisolone, vincristine, methotrexate, and 6-mercaptopurine)
Number of subjects: 73
Study 1203854 — intervention group
Group type: COMPARATOR
Intervention: VP (vincristine and prednisone)
Number of subjects: 73
Study 29175569 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tranexamic acid (10 mg/kg loading dose, then 1 mg·kg‐1·hr‐1 throughout surgery)
Number of subjects: 61
Study 29175569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 28332888 — intervention group
Group type: EXPERIMENTAL
Intervention: Home self‐collected HPV testing
Number of subjects: 1769
Study 28332888 — intervention group
Group type: COMPARATOR
Intervention: Clinician‐collected Pap screening
Number of subjects: 1769
Study 28332888 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐collected HPV test recommendation by clinicians
Number of subjects: 1769
Study 26160625 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily administration of perindopril (4 mg morning and 4 mg evening)
Number of subjects: 164
Study 26160625 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily administration of losartan (50 mg morning and 50 mg evening)
Number of subjects: 164
Study 26160625 — intervention group
Group type: COMPARATOR
Intervention: Once-daily evening administration of perindopril (8 mg)
Number of subjects: 164
Study 26160625 — intervention group
Group type: COMPARATOR
Intervention: Once-daily evening administration of losartan (100 mg)
Number of subjects: 164
Study 23293945 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzathine penicillin G (generic formulation, 1,200,000 IU)
Number of subjects: 12
Study 23293945 — intervention group
Group type: COMPARATOR
Intervention: Retarpen® 1.2 million units (innovator's product)
Number of subjects: 12
Study 20841410 — intervention group
Group type: EXPERIMENTAL
Intervention: vitalHEAT system (circulating-water sleeve on 1 arm)
Number of subjects: 71
Study 20841410 — intervention group
Group type: COMPARATOR
Intervention: Forced air warming cover (upper-body)
Number of subjects: 71
Study 20841410 — intervention group
Group type: COMPARATOR
Intervention: Comparison of vitalHEAT to forced air
Number of subjects: 71
Study 17387314 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-h arm crank ergometer exercise at 60% of VO(2max)
Number of subjects: 13
Study 16198030 — intervention group
Group type: COMPARATOR
Intervention: Female athletes during medial drop landing
Number of subjects: 22
Study 16198030 — intervention group
Group type: COMPARATOR
Intervention: Female athletes during lateral drop landing
Number of subjects: 22
Study 16198030 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral drop landing
Number of subjects: 22
Study 16198030 — intervention group
Group type: COMPARATOR
Intervention: Female athletes during medial drop task
Number of subjects: 22
Study 12957528 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraluminal aortoplasty
Number of subjects: 0
Study 12957528 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic resection
Number of subjects: 0
Study 10683714 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% solution of Citrus limon and Cydonia oblongata
Number of subjects: 18
Study 10683714 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% solution of Citrus limon and Cydonia oblongata
Number of subjects: 18
Study 10683714 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 18
Study 8973432 — intervention group
Group type: EXPERIMENTAL
Intervention: Solar treatment (water left in full sunlight)
Number of subjects: 206
Study 8973432 — intervention group
Group type: COMPARATOR
Intervention: Control (water kept indoors in the shade)
Number of subjects: 206
Study 1317657 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH 10,000 U pre-HD (Group A)
Number of subjects: 29
Study 1317657 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH 5000 U pre-HD (Group B)
Number of subjects: 29
Study 1317657 — intervention group
Group type: COMPARATOR
Intervention: LMWH 5000 U pre-HD (Group C)
Number of subjects: 29
Study 1317657 — intervention group
Group type: COMPARATOR
Intervention: H (Group AII)
Number of subjects: 29
Study 1317657 — intervention group
Group type: COMPARATOR
Intervention: L (Group BII)
Number of subjects: 29
Study 1317657 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH (all groups)
Number of subjects: 29
Study 6376480 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (5 mg)
Number of subjects: 27
Study 6376480 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (5 mg)
Number of subjects: 27
Study 30871628 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance rituximab
Number of subjects: 0
Study 30871628 — intervention group
Group type: COMPARATOR
Intervention: No additional rituximab (non-maintenance)
Number of subjects: 0
Study 30871628 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (induction therapy)
Number of subjects: 0
Study 29601278 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy with posthypnotic suggestions delivered once a week over 6 months
Number of subjects: 60
Study 29601278 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study 25648736 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat high-carbohydrate diet
Number of subjects: 102
Study 25648736 — intervention group
Group type: COMPARATOR
Intervention: Moderate-fat diet
Number of subjects: 102
Study 25648736 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie low-fat high-carbohydrate diet
Number of subjects: 102
Study 24692301 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple DMARD therapy + IM glucocorticoids
Number of subjects: 0
Study 24692301 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple DMARD therapy + oral glucocorticoids
Number of subjects: 0
Study 24692301 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX treatment
Number of subjects: 0
Study 24692301 — intervention group
Group type: EXPERIMENTAL
Intervention: HCQ treatment
Number of subjects: 0
Study 24692301 — intervention group
Group type: EXPERIMENTAL
Intervention: MTXGlu2
Number of subjects: 0
Study 24692301 — intervention group
Group type: EXPERIMENTAL
Intervention: MTXGlu3
Number of subjects: 0
Study 24692301 — intervention group
Group type: EXPERIMENTAL
Intervention: MTXGlu4
Number of subjects: 0
Study 24692301 — intervention group
Group type: EXPERIMENTAL
Intervention: MTXGlu5
Number of subjects: 0
Study 24692301 — intervention group
Group type: EXPERIMENTAL
Intervention: Total MTXGlu
Number of subjects: 0
Study 24692301 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort
Number of subjects: 0
Study 22974280 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg once daily for 18 weeks
Number of subjects: 227
Study 22974280 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 18 weeks, then glimepiride 1-4 mg once daily for 34 weeks
Number of subjects: 227
Study 22974280 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin during 34-week extension
Number of subjects: 227
Study 22974280 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride during 34-week extension
Number of subjects: 227
Study 20179613 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal clipping
Number of subjects: 30
Study 20179613 — intervention group
Group type: COMPARATOR
Intervention: No clipping (control)
Number of subjects: 30
Study 18071098 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized psychosocial intervention study
Number of subjects: 0
Study 18071098 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants in the psychosocial intervention
Number of subjects: 0
Study 18071098 — intervention group
Group type: COMPARATOR
Intervention: Non-participants
Number of subjects: 0
Study 15597185 — intervention group
Group type: EXPERIMENTAL
Intervention: Foreground elements
Number of subjects: 0
Study 15597185 — intervention group
Group type: COMPARATOR
Intervention: Background elements
Number of subjects: 0
Study 11984518 — intervention group
Group type: EXPERIMENTAL
Intervention: Real exercise program (head-raising exercise) for 6 weeks
Number of subjects: 27
Study 11984518 — intervention group
Group type: COMPARATOR
Intervention: Sham exercise
Number of subjects: 27
Study 11984518 — intervention group
Group type: EXPERIMENTAL
Intervention: Real exercise program (after crossover from sham)
Number of subjects: 27
Study 11984518 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire group (27 patients) before and after exercise
Number of subjects: 27
Study 9860151 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin with ammonium chloride (acidification)
Number of subjects: 9
Study 9860151 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin with sodium bicarbonate (alkalinization)
Number of subjects: 9
Study 9860151 — intervention group
Group type: COMPARATOR
Intervention: Control (no acidification or alkalinization)
Number of subjects: 9
Study 7896655 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone, 1.0 mg/kg, daily
Number of subjects: 13
Study 2654391 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-8980
Number of subjects: 107
Study 2654391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 199128 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of naloxone
Number of subjects: 0
Study 199128 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 6939007 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 0
Study 6939007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30328210 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis to Peritoneal Dialysis (HD to PD)
Number of subjects: 911
Study 30328210 — intervention group
Group type: COMPARATOR
Intervention: Initiated and remained on Peritoneal Dialysis (PD)
Number of subjects: 911
Study 29306609 — intervention group
Group type: EXPERIMENTAL
Intervention: MED2005 (0.2% glyceryl trinitrate topical gel)
Number of subjects: 232
Study 29306609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 26439240 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.3 mg (oral single dose)
Number of subjects: 12
Study 26439240 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 12
Study 25271602 — intervention group
Group type: EXPERIMENTAL
Intervention: Introduction of dietary gluten at 6 months (group A)
Number of subjects: 832
Study 25271602 — intervention group
Group type: COMPARATOR
Intervention: Introduction of dietary gluten at 12 months (group B)
Number of subjects: 832
Study 25271602 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk HLA genotype
Number of subjects: 832
Study 25271602 — intervention group
Group type: COMPARATOR
Intervention: Standard-risk HLA genotype
Number of subjects: 832
Study 22534709 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg qd)
Number of subjects: 19
Study 22534709 — intervention group
Group type: COMPARATOR
Intervention: Sulfadiazine and Pyrimethamine
Number of subjects: 19
Study 19067166 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicago Parent Program (CPP)
Number of subjects: 253
Study 19067166 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 253
Study 17161554 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year post-radiotherapy prostate biopsy
Number of subjects: 164
Study 16447644 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Laryngoscope (DLS)
Number of subjects: 43
Study 16447644 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic Bronchoscope (FOB)
Number of subjects: 43